JUMP REPORT
Avg Daily Volume: 795,234 Market Cap: 812.56M
Sector: Services Short Interest: 14.11
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .03/share REV: 37.99/M
___________________________________________________________
LAST QTR: EPS: .01/share ACTUAL: .04/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .01/share REV: 38.9/M
______________________________________________________
FULL YR: EPS: .13/share REV: 164.68/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
__________________________________________________________________
BEAT/MISS RECORD: –% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -13.59, 9.11, 12.55
EXPECTED JUMP MOVE: 10-15%
——–
*** With market volatility at extremes during the coronavirus pandemic there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading.
Links To Latest News and Headlines
CareDx, Inc. previously announced that Medicare finalized a Local Coverage Determination for molecular testing to monitor solid organ transplant rejection, affirming coverage for its AlloSure Kidney, AlloMap and AlloSure Heart, and AlloSure Lung surveillance tests with defined testing limits over the first three years post-transplant. This decision removes a key reimbursement uncertainty for CareDx’s core transplant-testing portfolio, clarifying how frequently clinicians can use these…
CareDx (CDNA) is back in focus after Medicare finalized a Local Coverage Determination for molecular testing in solid organ transplants, confirming reimbursement for the company’s kidney, heart, and lung transplant surveillance portfolio. See our latest analysis for CareDx. The finalized Medicare LCD arrives after a sharp swing in sentiment around CareDx, with a 30 day share price return of 69.21% and a 1 year total shareholder return of 233.45%, even though the 5 year total shareholder…
CareDx stock has delivered a very strong 273.8% return over the past three years. However, its current valuation checks and recent share price strength point to a stock that may now be leaning expensive rather than clearly mispriced. Over the last three years, CareDx has returned 273.8%. This puts extra focus on whether the current price still reflects a reasonable balance between potential and risk. The finalization of Medicare coverage for CareDx’s solid organ transplant molecular tests…
CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.
Final Medicare policy supports transplant surveillance portfolioCareDx Inc. (NASDAQ:CDNA) shares climbed 20% on Thursday after the company announced that Medicare had finalized its Local Coverage Determination (LCD) covering molecular testing for solid organ transplant rejection.
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.